INTRODUCTION
Triple-negative breast cancer (TNBC), a phenotypic subtype defined by a lack of hormonal (estrogen and progesterone) receptors and human epidermal growth factor receptor 2 (HER2) expression, accounts for 10% to 20% of all breast cancers and is associated with a more aggressive disease course. 1, 2 Non-Hispanic black women in the United States are reported to have the highest rate of TNBC (27.2 per 100,000 women) and proportionally, rates of TNBC (vs other subtypes) are higher in younger women compared with older women. 3 However, approximately one-third of all TNBC cases in the United States are diagnosed among women aged 65 years (age-adjusted rate of 36.2 per 100,000 women). taxane regimens, 6 therefore limiting the potential for the efficacious use of those drugs after disease recurrence. For women diagnosed with advanced TNBC (American Joint Commission on Cancer [AJCC] stages III and IV disease), conventional treatment includes cytotoxic chemotherapy, with several preferred regimens 6 ; however, to the best of our knowledge, there is no optimal choice or guideline alignment. 7 With the aggressive nature of TNBC, 8 and national health expenditures increasing at a rate of 5% to 6% annually, 9 it is important to attempt to determine the most efficacious treatments for this disease. US health care providers and policymakers have increasingly emphasized the importance of evaluating the economic burden of cancer and the benefits of medical interventions, especially new therapies, to support pricing and reimbursement. 10 This study of patients with advanced TNBC within the SEER-Medicare linked database had the following objectives: 1) to identify and characterize elderly patients with advanced TNBC with respect to baseline demographics and comorbidities; 2) to describe treatment, including chemotherapy regimens, by specific type of therapy; 3) to describe survival patterns; and 4) to measure health care resource use (HRU) and costs.
MATERIAL AND METHODS

Study Population
Women with incident AJCC stage III/IV TNBC diagnosed between January 1, 2007, and January 1, 2011, were selected from the SEER-Medicare database that links cancer registry information in selected US geographic areas with claims for covered health care services of Medicare beneficiaries. The SEER program represents approximately 28% of the US population, whereas Medicare covers health services for approximately 97% of individuals aged 65 years. Approximately 55% of SEER patients are aged 65 years and approximately 94% have been successfully linked with their Medicare claims. 4, 11, 12 Geographic areas selected for inclusion in SEER are based on adherence to operating and maintaining high-quality, population-based cancer reporting systems and specific patient populations of interest. 13 The Wayne State University institutional review board determined that the study was nonhuman participant research (HPR# 2015-48) .
The SEER-Medicare database analytic variables included patient demographics (eg, age and sex); tumor characteristics; health plan enrollment information; facility revenue codes; place of service; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnoses and procedures codes; Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology (CPT) codes; and prescription claims data for each patient and associated cost.
Because HER2 status first was included in the SEER data in 2010, breast cancer diagnoses made before 2010 were identified as TNBC using a combination of the estrogen receptor (ER) and progesterone receptor (PR) codes and lack of HER2-target medication claims, as was done in a previous study.
14 To determine the accuracy of this algorithm, we searched for trastuzumab claims among the patients with stage III and stage IV, ER-negative and PR-negative breast cancer who were diagnosed in 2010 and 2011 and who were identified in SEER as having known HER2 receptor status. We found that of 399 women with negative HER2 status, 386 (96.7%) had no trastuzumab claim (positive predictive value, 88.3%).
Women were included in the analysis if they were enrolled in Medicare Parts A and B for the 12 months before diagnosis and for at least 2 years after diagnosis (or until death if survival was <2 years), and were aged 66 years at the time of diagnosis. These restrictions ensured that patient characteristics and modified Charlson Comorbidity Index (CCI) scores could be calculated. 15, 16 Patients who were members of a health maintenance organization were excluded to avoid bias in the HRU and cost outcomes. Other exclusion criteria were applied as indicated in Figure 1 . Lines of chemotherapy were defined using previously published methods 17 ; specifically, firstline agents had to be given after the diagnosis of stage III/ IV disease and included any additional agents given in the next 15 days. Subsequent lines of therapy were identified by either a change in the therapeutic agent or by a gap of 120 days of the same agent given in the first-line setting.
Statistical Analysis
All statistical analyses were stratified by AJCC stage (stage III vs stage IV). Descriptive statistics (numbers and percentages, means and standard deviations) were used to evaluate the demographic and clinical characteristics of patients with advanced TNBC and to describe the therapies used, HRU, and costs. The distribution of demographic and other clinical characteristics by AJCC stages III and IV were compared using the Mantel-Haenszel test for trend for ordinal variables (age group, year of diagnosis, poverty, and modified CCI), and the chi-square test was used for categorical variables (race/ethnicity, SEER region, rural status, marital status, and vital status). In addition, the distribution of treatment received was compared by AJCC stage using chi-square tests.
OS was calculated from the time of diagnosis to the time of death due to any cause. Patients without documented death at the time of last follow-up were censored at the end of the follow-up period (12/31/2013) . In addition, survival from the time of the initiation of a specific chemotherapy line was calculated from the date of the chemotherapy line to the date of death or end of study follow-up. Means and medians of survival were calculated as well as survival rates at 1 year and 3 years with 95% confidence intervals (95% CIs).
HRU and costs for the entire study observation period and for 3 time periods (last quarter, initial quarter, and intervening) were calculated, similar to the model proposed by Yabroff et al. 18 The initial quarter included the first 3 months after diagnosis. The last quarter, calculated only among those cases who died within the study period, was the last 3 months of life. The intervening time period started at the fourth month after diagnosis to the end of follow-up (for patients alive at the end of followup) or 3 months before death (for patients who died during follow-up). Time was allocated in a sequential manner to each time period starting with the last quarter, followed by the initial quarter and then the intervening time. Due to the short survival period for some cases of advanced TNBC, not all cases contributed time to each period. HRU and costs were stratified further by type: inpatient hospitalization; skilled nursing admission; outpatient visits; outpatient emergency department; durable medical equipment; home health care; hospice; pharmacy (only among those individuals enrolled in Medicare Part D from the time of diagnosis to the end of study observation [527 individuals]); and noninstitutional services for inpatient, skilled nursing, outpatient, and emergency department. Costs were adjusted for inflation using 2013 as the reference (https://www.bls.gov/data/inflation_calculator. htm).
Statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina).
RESULTS
We identified 1244 patients newly diagnosed with stage III/IV advanced TNBC between 2007 and 2011 who were enrolled in Medicare Parts A and B (Fig. 1) . Table 1 shows the patient characteristics at the time of diagnosis, stratified by AJCC stage of disease among a cohort of women with TNBC diagnosed between 2007 and 2014. The majority of patients were aged >75 years (61.0% of patients with stage III and 57.4% of patients with stage IV disease). There was a higher percentage of non-Hispanic black patients diagnosed with stage IV disease (20.7%) compared with stage III disease (14.1%) (P 5 .002) and women with stage IV disease were more likely to live in a high poverty area ranked as 20% to 100% poverty (30.4%) compared with women with stage III disease (22.4%) (P 5 .011). Women with stage IV disease were more likely to be single (11.8%) compared with those with stage III disease (7.0%) (P 5 .029), and were more likely to die of breast cancer by the end of the study (73.1% vs 41.5%) (P<.001). There was no difference noted with regard to age distribution, SEER region, year of diagnosis, rural status, or CCI for women with stage III versus stage IV disease. An evaluation of first-line chemotherapy regimens demonstrated that combination therapies were more common among patients with stage III compared with stage IV disease, with the most common being cyclophosphamide plus doxorubicin, followed by paclitaxel and cyclophosphamide plus docetaxel (Table 3 ). For patients with stage III disease, paclitaxel was the most common agent given as second-line or third-line therapy. Taxanes and anthracyclines were the most common chemotherapy classifications given as first-line and second-line treatment for both stage III and stage IV disease. Gemcitabine and vinorelbine often were used as second-line and third-line agents. Platinum-based compounds were used only in patients with stage IV disease.
The median OS was 18 months for all patients ( Table 4 ). The median OS for patients with stage III disease was 30 months, compared with 5 months for patients with stage IV disease. Among patients with stage III disease, those with the longest median OS (42 months; 95% CI, 38-47 months) had undergone both surgery and chemotherapy, compared with other treatment modalities. Surgery with chemotherapy also was associated with the longest median OS for patients with stage IV disease (15 months; 95% CI, 11-23 months). For patients with stage III disease who received chemotherapy, the percentage alive at 3 years was similar regardless of the number of lines received, at approximately 50%. For patients with stage IV disease, there appeared to be a survival benefit for women who received >1 line of chemotherapy, but the numbers were small and those individuals with more aggressive disease would have died before receiving additional lines of chemotherapy. The total mean monthly costs per patient for patients with stage IV disease were greater than for patients with stage III disease for each of the 3 time periods ($9456 vs $6837 for the initial quarter, $5773 vs $3651 for the intervening period, and $9959 vs $8096 for the last quarter) ( Table 5 ). Across all 3 time periods, the mean cost per patient-month was $4810 for patients with stage III disease and $9159 for patients with stage IV disease. Although the mean number of hospitalizations was similar for the 2 disease stages, the cost per patient-month was consistently higher for patients with stage IV disease. Similarly, despite having a similar or lower number of monthly claims in the 3 time periods for outpatient physician costs, the mean cost per patient-month was the same or greater for patients with stage IV disease compared with patients with stage III disease. Hospice claims and charges were greater for patients with stage IV disease compared with stage III disease in the initial and intervening time periods, but was lower during the last quarter. Pharmacy costs did not appear to fluctuate significantly across time periods or stages of disease.
DISCUSSION
To our knowledge, the current study is the first to provide a complete narrative of treatment, survival, HRU, and costs for newly diagnosed, advanced stage TNBC among older women in the United States. Although nonHispanic black women are reported to have the highest incidence of TNBC at all ages, 19,20 a substantial percentage of the women in the current study cohort were nonHispanic white. The clinical features of TNBC tumors in the current study cohort were similar to those described for all TNBC tumors in that the most common histology was ductal and a large percentage of the tumors were classified as poorly differentiated. [20] [21] [22] Treatment regimens were diverse in this patient population, but generally followed national guidelines. Compared with patients with stage III disease, those with stage IV disease had lower rates of breast cancer-directed therapy. Women with both stages of disease were found to have similar numbers of hospitalizations and emergency department visits, yet costs were greater among patients with stage IV disease compared with patients with stage III disease, due in part to the greater use of hospice services in the initial and intervening months after diagnosis.
The current study cohort had a pattern of comorbidities that was similar to that found by other investigators examining patients with breast cancer in the SEERMedicare database 23 ; however, the current study cohort with stage III and stage IV TNBC had, in general, a lower percentage of women with a CCI of 0 and a greater percentage of women with a CCI 3. Nevertheless, approximately 75% of the current study cohort had a CCI of either 0 or 1 compared with a rate of 86% reported among all SEER-Medicare patients with breast cancer. 23 Current recommendations suggest that older women with no or minimal comorbidities should receive the same treatment of TNBC as younger women. 24 Yet approximately 26.4% of women with stage IV TNBC received no breast cancerdirected treatment (surgery, radiotherapy, or chemotherapy) compared with 4.1% of women with stage III disease. As expected, women with stage IV breast cancer were more likely to receive chemotherapy without surgery than those with stage III disease (31.3% vs 4.6%); however, we noted that approximately 40% of women with stage III and 45% of those with stage IV disease in the current study cohort received no chemotherapy. Potential factors involved in the decision not to undergo chemotherapy include advanced age, significant comorbidities, fear of side effects, or anticipation of a decreased quality of life. [25] [26] [27] Our hypothesis was that because approximately 75% of the women in the current study cohort had a CCI of either 0 or 1, their systemic treatment would follow national guidelines. 24 The current National Comprehensive Cancer Network (NCCN) guidelines for HER2-negative, stage III disease include 10 combination chemotherapy regimens, 6 with the preferred being: 1) doxorubicin and cyclophosphamide followed by paclitaxel; and 2) docetaxel and cyclophosphamide. In the current study, these 2 regimens were the top 2 most common adjuvant therapies for patients with stage III disease. Other single agents, including taxanes, or the combination of cyclophosphamide and doxorubicin alone also were found to be within the top 5 adjuvant treatments for stage III disease. For women with stage IV disease, the NCCN guidelines include 14 single agents and 9 chemotherapy combinations. 6 The NCCN guidelines indicate that there is no compelling evidence that combination agents are superior to sequential single agents for the treatment of stage IV disease; however, in practice, combination agents frequently are used in the setting of visceral crisis. As expected, single-agent taxanes were the first and second most common treatments used in the first-line setting for patients with stage IV disease, and combinations using taxanes also were among the top 5 choices for first-line chemotherapy and were common choices for second-line and third-line treatments as well. This reliance on taxanes is not surprising because their efficacy has been established in the settings of neoadjuvant, adjuvant, and metastatic TNBC. [28] [29] [30] For patients with stage III and stage IV disease, we found longer survival among those who received both surgery and chemotherapy, compared with patients treated with surgery alone or chemotherapy alone. There also appeared to be a survival advantage with additional lines Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; NC, not calculable; OS, overall survival; SE, standard error; SEER, Surveillance, Epidemiology, and End Results; TNBC, triple-negative breast cancer. a Chemotherapy was given after surgery (ie, does not include neoadjuvant chemotherapy).
of chemotherapy. In both circumstances, the appearance of extended survival could be due to the fact that patients who survived to receive additional therapy may have been healthier to begin with or had less aggressive disease. In our cohort of patients with advanced TNBC, the initial and last quarter monthly costs for both women with stage III and those with stage IV disease were higher than those for the intervening period. End-of-life costs tend to be high regardless of the cause of death. 18 Ray et al reported a cost per patient of approximately $50,000 in the first 3 months after diagnosis for patients with metastatic breast cancer using the Truven Health MarketScan Research Databases. 31 In contrast, the current study identified a total cost per patient of approximately $28,000 in the first 3 months after diagnosis for patients with stage IV TNBC. The difference in costs may be due to: 1) the 32 which was similar to the per-patient-month cost for patients with stage IV TNBC noted in the current study ($9159 per patient-month).
A different analysis using the Impact Intelligence Oncology Management registry reported mean costs per year for patients with TNBC of $76,285, 33 or $6357 per month ($76,285/12 months). The results of the current study demonstrated a mean cost per patient-month of $4810 for patients with stage III disease and $9159 for patients with stage IV disease. Only 10.4% of the Impact Intelligence Oncology Management registry contained patients with stage IV TNBC, which may account for the differences in cost between our study and theirs. The OS rates at 1 and 3 years in the current study for patients with stage IV disease were 29% and 11%, respectively, and the OS rates for the Impact Intelligence Oncology Management TNBC cohort were approximately 70% and 23%, respectively, for patients with stage IV TNBC. 33 This difference again may be due to the number of patients with stage IV disease who opted for no breast cancer-directed treatment in the current study, which in turn may be due to the older age of the SEER-Medicare cohort. All of the patients in the current study cohort were aged 66 years, whereas only 18.2% of patients in the Impact Intelligence Oncology Management registry were within that age range. Furthermore, this registry included predominantly commercially insured patients, which may result in differences in practice patterns because there may be formulary placement or tier differences between drugs that are available to commercially-insured versus Medicare-insured patients.
More recently, Allaire et al conducted a study of breast cancer costs among younger women by linking private insurers' enrollment files with cases identified in the population-based North Carolina SEER registry. 34 They found that the cost for all service types for the first year after diagnosis was $80,578 for women aged 45 to 64 years, which is equivalent to $6714 per month. This is similar to the cost per month reported by the Impact Intelligence Oncology Management registry, 33 and between the average costs we found of $4810 for patients with stage III disease and $9159 for patients with stage IV disease. Allaire et al included all stages of disease in their analysis, whereas we focused on patients with stage III and stage IV disease.
Although the focus of the study by Allaire et al 34 was on the excess costs of breast cancer compared with women without breast cancer, they found that patients with stage III/IV disease had higher costs, regardless of age group, than patients diagnosed at earlier stages.
The limitations of the current study data include the lack of HER2 status as a collected variable in SEER for 3 years of our study. We instead used an algorithm identifying probable HER2-negative women by a lack of treatment with trastuzumab, 14 which may misclassify some HER2-positive patients who elected not to receive any type of chemotherapy. In addition, due to excluding patients with Medicare managed care plans, these results are not necessarily representative of all women in Medicare. Because TNBC is more common among younger women compared with other breast cancer phenotypes, 21 studies of TNBC usually focus on a younger population. The population-based SEER-Medicare database allowed us to focus on older women, who comprise a substantial percentage of patients with TNBC. Thus, the current study addresses a gap in the literature by characterizing the treatment, survival, and HRU among older women with advanced TNBC.
The results of the current study demonstrate that advanced TNBC among older women has histological characteristics of poor differentiation, which indicates an aggressive behavior. In addition, survival was poor, with only 33% of patients with stage III disease and 11% of patients with stage IV disease still alive at 3 years. Advanced TNBC remains a difficult cancer to treat, with to the best of our knowledge no consensus regarding a preferred regimen. The majority of the health care costs associated with advanced TNBC occur in the initial months after diagnosis and the last months before death, with a monthly mean cost of approximately $4810 for patients with stage III disease and $9159 for patients with stage IV disease. Clearly, additional research is required to develop more costeffective and clinically beneficial treatments with which to alleviate the clinical and economic burden of elderly patients in the United States with advanced TNBC.
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